Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer

Expert Review of Molecular Diagnostics

Volumn 13, Issue 5, 2013, Pages 425-430

  Frampton, Adam E ^a   Fletcher, Claire E ^a   Gall, Tamara M H ^a   Castellano, Leandro ^a   Bevan, Charlotte L ^a   Stebbing, Justin ^b   Krell, Jonathan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

biomarker; CA19 9; diagnostic; miR 27a; miRNA; pancreatic ductal adenocarcinoma; peripheral blood mononuclear cells

Indexed keywords

CA 19-9 ANTIGEN; MICRORNA; MICRORNA 15B 5P; MICRORNA 16 5P; MICRORNA 26A 5P; MICRORNA 27A 3P; MICRORNA 342 3P; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL ISOLATION; COHORT ANALYSIS; GENE EXPRESSION; HUMAN; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; SENSITIVITY AND SPECIFICITY; TUMOR IMMUNITY; UPREGULATION;

ADENOCARCINOMA; CA-19-9 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; PANCREATIC NEOPLASMS;

EID: 84879347993     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.31     Document Type: Article

References (31)

1. Baine MJ, Chakraborty S, Smith LM et al. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS ONE 6(2), e17014 (2011).
2. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51(6), 293-298 (2002).
3. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009).
4. Eruslanov E, Neuberger M, Daurkin I et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int. J. Cancer 130(5), 1109-1119 (2012).
5. Whitney AR, Diehn M, Popper SJ et al. Individuality and variation in gene expression patterns in human blood. Proc. Natl Acad. Sci. USA 100(4), 1896-1901 (2003).
6. Showe MK, Vachani A, Kossenkov AV et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small-cell lung cancer from patients with nonmalignant lung disease. Cancer Res. 69(24), 9202-9210 (2009).
7. Baine MJ, Mallya K, Batra SK. Quantitative real-time PCR expression analysis of peripheral blood mononuclear cells in pancreatic cancer patients. Methods Mol. Biol. 980, 157-173 (2013).
8. Friso S, Udali S, Guarini P et al. Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk. Cancer Epidemiol. Biomarkers Prev. 22(3), 348-355 (2013).
9. Zhou H, Guo JM, Lou YR et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. 88(7), 709-717 (2010).
10. Wang WS, Liu LX, Li GP et al. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev. Res. (Phila.) 6(4), 331-338 (2013).
11. Yamamoto T, Yanagimoto H, Satoi S et al. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J. Surg. Res. 173(2), 299-308 (2012).
12. Yamamoto T, Yanagimoto H, Satoi S et al. Circulating CD4+ CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 41(3), 409-415 (2012).
13. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 33(3), 266-270 (2007).
14. Gall TM, Frampton AE, Krell J, Castellano L, Jiao LR. Circulating molecular markers in pancreatic cancer: ready for clinical use? Future Oncol. 9(2), 141-144 (2013).
15. Zhao F, Obermann S, von Wasielewski R et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 128(1), 141-149 (2009).
16. Kong X, Du Y, Wang G et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig. Dis. Sci. 56(2), 602-609 (2011).
17. Liu R, Chen X, Du Y et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 58(3), 610-618 (2012).
18. Twine NC, Stover JA, Marshall B et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 63(18), 6069-6075 (2003).
19. Huang H, Dong X, Kang MX et al. Novel blood biomarkers of pancreatic cancerassociated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am. J. Gastroenterol. 105, 1661-1669 (2010).
20. Liu T, Tang H, Lang Y, Liu M, Li X. microRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 273(2), 233-242 (2009).
21. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL. Androgen-regulated processing of the oncomir miR-27a, which targets prohibitin in prostate cancer. Hum. Mol. Genet. 21(14), 3112-3127 (2012).
22. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 67(22), 11001-11011 (2007).
23. Kawaguchi T, Komatsu S, Ichikawa D et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br. J. Cancer 108(2), 361-369 (2013).
24. Baraniskin A, Nöpel-Dünnebacke S, Ahrens M et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int. J. Cancer 132(2), E48-E57 (2013).
25. Yabushita S, Fukamachi K, Tanaka H et al. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Pancreas 41(7), 1013-1018 (2012).
26. Bauer AS, Keller A, Costello E et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS ONE 7(4), e34151 (2012).
27. Morimura R, Komatsu S, Ichikawa D et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br. J. Cancer 105(11), 1733-1740 (2011).
28. Liu J, Gao J, Du Y et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int. J. Cancer 131(3), 683-691 (2012).
29. LaConti JJ, Shivapurkar N, Preet A et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS ONE 6(6), e20687 (2011).
30. Li A, Omura N, Hong SM et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 70(13), 5226-5237 (2010).
31. Wang J, Chen J, Chang P et al. microRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila.) 2(9), 807-813 (2009).